Q2B25 Paris | Phalgun  Lolur, Scientific Quantum Development Lead, Capgemini @QCWare
Q2B25 Paris | Phalgun  Lolur, Scientific Quantum Development Lead, Capgemini  @QCWare
Uploaded October 2025 | Updated September 2026, 2 weeks ago
A Utility Scale Perspective on Reactivity Prediction:

In the NISQ era, simulating complex molecular systems like sulfonyl fluoride-containing drug candidates requires quantum algorithms that minimize circuit depth to suit current hardware limitations. By integrating Hamiltonian truncation, Clifford Decomposition and Transformation (CDAT), and optimized transpilation, we achieved up to a 28.5-fold reduction in circuit depth, enabling one of the largest electronic structure Hamiltonian dynamics simulations on IBMQ’s Heron architecture with direct relevance to pharmaceutical development.

q2b.qcware.com
Q2B25 Paris | Phalgun  Lolur, Scientific Quantum Development Lead, CapgeminiQ2B26 Tokyo | Shu Tanaka, Professor, Faculty of Science and Technology, Keio UniversityQ2B25 Paris | Dr. Vito Giovanni Lucivero, CEO & Founder, QSENSATOQ2B25 Silicon Valley | Doug Finke, Chief Content Officer, GQIQ2B25 Paris | Matt Johnson, CEO, QC Ware CorpQ2B25 Paris | Stefan  Ostermann, Quantum Applications Manager, QuEra Computing IncQ2B25 Paris | Loic Le Loarer, Head of Quantum, SGPIQ2B26 Tokyo | Daisuke Tanaka, CEO, Quanmatic Inc.Q2B25 Silicon Valley | Matt Johnson, CEO, QC Ware Corp.Q2B25 Paris | Fabio Beltram, National Quantum Science and Technology InstituteQ2B25 Paris | Bruno Sanglé Ferriere, CEO, Carrousel Digital
QC Ware |

Q2B25 Paris | Phalgun Lolur, Scientific Quantum Development Lead, Capgemini

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER